United Therapeutics Corporation $UTHR Shares Bought by Swedbank AB

Swedbank AB grew its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 0.7% during the first quarter, HoldingsChannel reports. The firm owned 327,122 shares of the biotechnology company’s stock after acquiring an additional 2,350 shares during the period. Swedbank AB’s holdings in United Therapeutics were worth $193,977,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Sage Rhino Capital LLC grew its position in shares of United Therapeutics by 5.1% in the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock valued at $281,000 after purchasing an additional 23 shares in the last quarter. Independent Advisor Alliance lifted its position in United Therapeutics by 3.3% during the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock worth $406,000 after buying an additional 27 shares in the last quarter. Florida Financial Advisors LLC boosted its stake in United Therapeutics by 5.4% during the fourth quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock worth $268,000 after buying an additional 28 shares during the last quarter. NDVR Inc. boosted its stake in United Therapeutics by 5.1% during the fourth quarter. NDVR Inc. now owns 616 shares of the biotechnology company’s stock worth $300,000 after buying an additional 30 shares during the last quarter. Finally, Principal Securities Inc. grew its holdings in United Therapeutics by 4.7% in the 4th quarter. Principal Securities Inc. now owns 686 shares of the biotechnology company’s stock valued at $334,000 after buying an additional 31 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at United Therapeutics

In related news, CFO James Edgemond sold 8,750 shares of the stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $538.15, for a total transaction of $4,708,812.50. Following the completion of the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at approximately $10,158,119.40. This trade represents a 31.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $548.96, for a total transaction of $5,215,120.00. Following the completion of the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at $22,240,016.48. This trade represents a 19.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 622,718 shares of company stock worth $350,859,876 over the last three months. Insiders own 8.60% of the company’s stock.

Wall Street Analyst Weigh In

UTHR has been the subject of a number of recent research reports. HC Wainwright raised their target price on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Morgan Stanley set a $516.00 price target on shares of United Therapeutics in a research report on Thursday, May 7th. Bank of America upped their price objective on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a report on Tuesday, March 31st. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Finally, Royal Bank Of Canada decreased their target price on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR traded up $11.29 during mid-day trading on Tuesday, reaching $558.53. 142,871 shares of the company’s stock were exchanged, compared to its average volume of 494,474. The company’s 50-day moving average is $557.83 and its 200-day moving average is $528.36. The firm has a market capitalization of $23.71 billion, a price-to-earnings ratio of 20.62, a PEG ratio of 1.82 and a beta of 0.58. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same quarter last year, the firm posted $6.63 earnings per share. The firm’s quarterly revenue was down 1.6% on a year-over-year basis. As a group, equities analysts predict that United Therapeutics Corporation will post 26.63 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.